A study showed that hospitals bought by private equity firms were admitting disproportionately healthier patients with heart ...

Enlicitide decanoate demonstrated meaningful LDL lowering in patients with heterozygous familial hypercholesterolemia and ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

When the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the ...

Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), ...

Merck said early Monday that a new cholesterol-lowering pill worked well in two late-stage trials, boosting the stock in ...

A new method, based on the use of molecules known as polypurine hairpins, facilitates the uptake of cholesterol by cells and ...

First the background: What is evolocumab? It is an antibody against an enzyme called PCSK9. Since PCSK9 is a protease that breaks down the LDL receptor, itself the major clearance mechanism for ...

The PCSK9 enzyme has emerged as a viable therapeutic target, resulting in the approval of 2 monoclonal antibodies, alirocumab and evolocumab, and a small interfering RNA molecule, inclisiran ...

A protein called PCSK9 determines how pancreatic cancer cells metastasize to different parts of the body.

Richa Munjal considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs. The promise of a new era of cholesterol management, ...